$31.67
0.70% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
IE00B56GVS15
Symbol
ALKS

Alkermes Plc Stock price

$31.67
+4.67 17.30% 1M
+3.76 13.47% 6M
+2.91 10.12% YTD
+7.29 29.90% 1Y
+2.15 7.29% 3Y
+15.09 91.01% 5Y
-29.43 48.17% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.22 0.70%
ISIN
IE00B56GVS15
Symbol
ALKS
Sector
Industry

Key metrics

Market capitalization $5.22b
Enterprise Value $4.41b
P/E (TTM) P/E ratio 15.08
EV/FCF (TTM) EV/FCF 9.16
EV/Sales (TTM) EV/Sales 2.91
P/S ratio (TTM) P/S ratio 3.45
P/B ratio (TTM) P/B ratio 3.45
Revenue growth (TTM) Revenue growth -12.31%
Revenue (TTM) Revenue $1.51b
EBIT (operating result TTM) EBIT $391.12m
Free Cash Flow (TTM) Free Cash Flow $481.58m
Cash position $884.02m
EPS (TTM) EPS $2.10
P/E forward 27.40
P/S forward 3.77
EV/Sales forward 3.18
Short interest 11.23%
Show more

Is Alkermes Plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Alkermes Plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Alkermes Plc forecast:

9x Buy
60%
6x Hold
40%

Analyst Opinions

15 Analysts have issued a Alkermes Plc forecast:

Buy
60%
Hold
40%

Financial data from Alkermes Plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
1,514 1,514
12% 12%
100%
- Direct Costs 242 242
16% 16%
16%
1,272 1,272
12% 12%
84%
- Selling and Administrative Expenses 609 609
8% 8%
40%
- Research and Development Expense 244 244
27% 27%
16%
419 419
6% 6%
28%
- Depreciation and Amortization 28 28
56% 56%
2%
EBIT (Operating Income) EBIT 391 391
3% 3%
26%
Net Profit 353 353
19% 19%
23%

In millions USD.

Don't miss a Thing! We will send you all news about Alkermes Plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Alkermes Plc Stock News

Neutral
Investors Business Daily
one day ago
The top five biotech stocks today have several commonalities. Among them are strong ratings.
Positive
Seeking Alpha
19 days ago
The company's drug LYBALVI, approved for adults with Schizophrenia and bipolar I disorder, shows potential for label expansion to include pediatric patients to potentially boost revenue growth. The ongoing phase 3 ENLIGHTEN-Youth trial aims to evaluate LYBALVI's efficacy and safety in pediatric patients, with a primary completion date of September 2026. Long-term data indicates minimal weight g...
Neutral
Seeking Alpha
20 days ago
Alkermes plc (NASDAQ:ALKS ) Q1 2025 Results Conference Call May 1, 2025 8:00 AM ET Company Participants Sandy Coombs - Senior Vice President of Corporate Affairs and Investor Relations Richard Pops - Chairman and Chief Executive Officer Todd Nichols - Senior Vice President and Chief Commercial Officer Blair Jackson - Executive Vice President and Chief Operating Officer Craig Hopkinson - Chief M...
More Alkermes Plc News

Company Profile

Alkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include Aristada, which is used for the treatment of schizophrenia in adults; and Vivitrol, which is an injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.

Head office Ireland
CEO Richard Pops
Employees 1,800
Founded 2011
Website www.alkermes.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today